What diseases is Gefituzumab mainly used to treat?

Glofitumab (Glofitamab), trade name: Columvi, is an innovative bispecific monoclonal antibody developed by the Swiss company Roche. It targets the CD20 antigen on the surface of B cells and the CD3 antigen on the surface of T cells at the same time, activating the patient's own T cells to recognize, activate and attack malignant B cells. It has become an important breakthrough in the field of immuno-oncology treatment. Its first and currently main approved indication is the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma), especially those who have received two or more systemic therapies but have failed to respond.

DLBCL is a subtype of non-Hodgkin's lymphoma that has a rapid onset and is highly malignant. Traditional treatment is based on R-CHOP chemotherapy, but about 30%-40% of patients will relapse after treatment or fail to respond to treatment. For these patients, further treatment options are very limited. The emergence of gaffetuzumab provides this type of "high-risk refractory" patients with innovative non-chemotherapy, non-cell transfusion immunotherapy, which is especially suitable for patients who cannot tolerate CAR-T therapy or who have failed cell preparation.

In addition toDLBCL, clinical studies of gaffetumumab are also underway in other hematological tumors of B-cell origin, such as high-grade B-cell lymphoma, follicular lymphoma, and primary mediastinal large B-cell lymphoma. Currently, global multi-center trials are expanding its indication boundaries, especially in patients who have failed multiple lines of therapy. Geffirumab has demonstrated rapid response and a high complete response rate, and has been conditionally approved for use in the United States, the European Union and China.

In short, the main indication of gratinumab is DLBCL that is ineffective in traditional treatments.With the advancement of clinical research in the future, its application potential in other hematological tumors will also continue to be optimistic.

Reference materials:https://www.drugs.com/glofitamab.html